FOLFIRINOX De-Escalation in Advanced Pancreatic Cancer: A Multicenter Real-Life Study.

Hortense ChevalierAngélique VienotAstrid LièvreJulien EdelineFarid El HajbiCharlotte PeugniezDewi VernereyAurélia MeurissePascal HammelCindy NeuzilletChristophe BorgAnthony Turpin

Published in: The oncologist (2020)

FOLFIRINOX de-escalation and maintenance is a feasible strategy in advanced pancreatic cancer that decreases chemotherapy toxicity to improve both survival and quality of life. Survivals in patients with maintenance therapy are clinically meaningful. Fluoropyrimidine monotherapy maintenance seems to be as efficient as FOLFIRI and should be a reference arm in future pancreatic cancer maintenance trials.

Keyphrases

locally advanced
open label
oxidative stress
randomized controlled trial
cross sectional
mesenchymal stem cells
double blind